Pain Therapeutics, Durect rise sharply


Shares of Pain Therapeutics (PTIE) and Durect (DRRX) finish the day higher by 16% and 9% respectively.

When these two move together investors may be expecting some news out of Pfizer (PFE) regarding Remoxy.

PFE Q3 call is October 29

From other sites
Comments (7)
  • Bbloomlu
    , contributor
    Comments (312) | Send Message
     
    Why are the shareholders the last to get the news. Did someone say insider trading. Long and hopeful but have been disappointed for more than 10 years.
    17 Oct 2013, 04:41 PM Reply Like
  • popster76
    , contributor
    Comments (490) | Send Message
     
    Hold on and stay long PFE Bbloomlu and if you really care about your investment then stay involved and follow the companies in which you have a vested interest. By the way, if you are so disappointed in Pfizer for the last 10 years, you must also hate consistent dividends? Here's an idea, the stock price is up today so why don't you just sell PFE take your profit and invest elsewhere?
    17 Oct 2013, 05:31 PM Reply Like
  • taplinger
    , contributor
    Comments (348) | Send Message
     
    You're awfully harsh to Bbloomlu, Mr. popster76. Judging from the timing, he may have gotten in at a higher price than it closed today. And who wants to break even after 10 years? I seem to remember reading that PFE slashed their dividend in 2008 so it hasn't always been consistent.

     

    That said, I also believe it's good advice to stay long PFE. The new CEO is a breath of fresh air and this stock could have room to move along with what is now a good dividend.
    18 Oct 2013, 12:27 AM Reply Like
  • PJafferyAnalyst45
    , contributor
    Comments (81) | Send Message
     
    I don't know why investors are excited about Pfizer coming out with news regarding Remoxy? Remoxy is simply equivalent to Oxycontin which has been used to treat chronic pain for several years now. The REAL excitement should be about Durect's non-opiate painkiller Posidur. Pacira Pharmaceutical's stock took off shortly after Exparel(a similar non-opiate painkiller) was approved by the FDA back in October of 2011. Posidur is basically the same as Exparel, but has not been FDA approved yet.
    17 Oct 2013, 09:45 PM Reply Like
  • Jbgoose
    , contributor
    Comments (3247) | Send Message
     
    PJaff- DRRX and PTIE are traded together, often, the niche is ART (to stop dose dumping, IV use, snorting) with triggers of new legislation for C2 opiod treatments. I think you are aware of this; Remoxy is better compared to immediate release oxycodone - not an extended release OxyContin (already reformulated). The market for Remoxy is more an attempt to stop or slow the potential for abuse, diversion and a 'gateway' to worse drugs and lifestyle. Think, a 30 pill 5mg Percocet ($ENDP) script after a dental or sport related injury turning one into a heroin addict overnight, that's the reefer madness side who has the PR, lawmakers and legitimately the families of many destroyed lives behind it. That's another debate. Oxycodone is also more 'potent' than Morphine Sulphate, which in non IV, pill formulation carries a 'very limited potential for addiction, ie drug seeking behaviors' but has become a political hot button and a widespread health epidemic, peaking around 09/10 turning more people into heroin addicts as the pills go for $40 on the streets and a potent street baggie only $3-5 (Seattle is a good example- pill seizure, arrests down double digit from '09 but heroin is up triple). There is a big problem, to be clear, and like most I personally know people and have extended family who have been impacted, talking rehab to death. I've traded in and out of companies with mostly success in this niche even with strong opinions against ART mandates. When laws take away affordable and correctly used options that provide millions proper pain management, these people represent the vast majority. But as an investor, the reality is ART is here and will become more widely used, thus the potential for PTIE and the never ending roller coaster ride. On the flip side to ART, look into $ACRX, new delivery system for a generic med(s) to be used worldwide in every hospital, ambulance and clinic with pain management tools that lower risks of IV infections and provides better pain management for many scenarios. Lastly, disclosure and statement: While people are tired of 'pumpers and dumpers' or take credit that an article or a tweet results in parabolic market moves, but call for lawsuits every time a bet goes against them; the truth is they need to educate themselves before gambling in any spec play or just investing in any position in general. Period.
    19 Oct 2013, 01:52 PM Reply Like
  • popster76
    , contributor
    Comments (490) | Send Message
     
    You are right taplinger, I was too harsh and apologize to Bbloomlu, but have owned PFE for over 25 years and it has been very good to me. Agree the new CEO does know what he is doing, he developed a strategy and is implementing it very well. Would also say that Pjaffery is on point as a non-opiate painkiller is the holy grail of medical discovery and if successful would be huge blockbuster.
    18 Oct 2013, 02:34 PM Reply Like
  • taplinger
    , contributor
    Comments (348) | Send Message
     
    I can't tell you how much I admire an investor who has the fortitude to stick with a stock that goes from 48 to 12, slashes its dividend, and had a CEO that couldn't do anything right. Me, I wouldn't be able to sleep at night and I'd be having anxiety attacks constantly.

     

    Another holy grail is a pill that kills appetite and has no side effects. Back when Wyeth was American Home Products and before Pfizer acquired them they had it half right - the side effects hurt people so they got sued. My experience with pain killers is that if it's truly effective against moderate to severe pain, then it has an addiction and abuse potential, which is the problem with opiates.
    19 Oct 2013, 11:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs